Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioStem Technologies, Inc. (BSEM)
Fort Lauderdale, FL, US
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Based on only 2 articles — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.18% | -4.00% | -13.08% | -24.48% | +28.96% | +13.39% | -63.91% | +116.00% | +220.00% | -71.20% | +20.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
9.00
+133.8%
|
| Last Quarter | 1 |
9.00
+133.8%
|
| Last Year | 1 |
9.00
+133.8%
|
| All Time | 1 |
9.00
+133.8%
|
-
Revenue growth Biotechnology: +1.6%-84.3% Q1'26: -91.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-126.5% Q1'26: -405.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-22.9% Q1'26: +39.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1.5% Q1'26: -144.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-5.3% ★ Q1'26: -165.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-22.9% ★ Q1'26: -35.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.09× Q1'26: -0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.88M
est: 7.20M (-4.5%)
|
16.69M
est: 16.70M (-0.1%)
|
301.83M
est: 285.70M (+5.6%)
|
47.48M
est: 228.30M (-79.2%)
|
29.00M
29.00M – 29.00M
-87.3% YoY
|
70.69M
70.69M – 70.69M
+143.7% YoY
|
100.58M
100.58M – 100.58M
+42.3% YoY
|
117.24M
117.24M – 117.24M
+16.6% YoY
|
132.99M
132.99M – 132.99M
+13.4% YoY
|
| EBITDA |
-6.52M
est: -3.35M (-94.6%)
|
-7.55M
est: -7.77M (+2.8%)
|
31.49M
est: -82.58M (+138.1%)
|
-469.7K
est: -65.99M (+99.3%)
|
-8.38M
-8.38M – -8.38M
+87.3% YoY
|
-20.43M
-20.43M – -20.43M
-143.7% YoY
|
-29.07M
-29.07M – -29.07M
-42.3% YoY
|
-33.89M
-33.89M – -33.89M
-16.6% YoY
|
-38.44M
-38.44M – -38.44M
-13.4% YoY
|
| EBIT |
-6.76M
est: -3.67M (-84.3%)
|
-7.78M
est: -8.51M (+8.6%)
|
31.20M
est: -89.45M (+134.9%)
|
-689.1K
est: -71.48M (+99.0%)
|
-9.08M
-9.08M – -9.08M
+87.3% YoY
|
-22.13M
-22.13M – -22.13M
-143.7% YoY
|
-31.49M
-31.49M – -31.49M
-42.3% YoY
|
-36.70M
-36.70M – -36.70M
-16.6% YoY
|
-41.64M
-41.64M – -41.64M
-13.4% YoY
|
| Net Income |
-7.07M
est: -4.12M (-71.6%)
|
-8.48M
est: 12.15M (-169.8%)
|
31.88M
est: 23.59M (+35.2%)
|
-6.58M
est: 4.35M (-251.3%)
|
-32.62M
-32.62M – -32.62M
-850.0% YoY
|
-4.18M
-4.18M – -4.18M
+87.2% YoY
|
10.54M
10.54M – 10.54M
+352.0% YoY
|
16.90M
16.90M – 16.90M
+60.3% YoY
|
19.24M
19.24M – 19.24M
+13.9% YoY
|
| SGA |
10.21M
est: 8.46M (+20.6%)
|
22.63M
est: 19.63M (+15.3%)
|
254.75M
est: 311.21M (-18.1%)
|
37.82M
est: 248.68M (-84.8%)
|
31.59M
31.59M – 31.59M
-87.3% YoY
|
77.01M
77.01M – 77.01M
+143.7% YoY
|
109.56M
109.56M – 109.56M
+42.3% YoY
|
127.70M
127.70M – 127.70M
+16.6% YoY
|
144.86M
144.86M – 144.86M
+13.4% YoY
|
| EPS |
-0.62
est: -0.19 (-226.3%)
|
-0.62
est: 0.56 (-210.7%)
|
1.95
est: 1.41 (+38.3%)
|
-0.39
est: 0.26 (-250.0%)
|
-1.95
-1.95 – -1.95
-850.0% YoY
|
-0.25
-0.25 – -0.25
+87.2% YoY
|
0.63
0.63 – 0.63
+352.0% YoY
|
1.01
1.01 – 1.01
+60.3% YoY
|
1.15
1.15 – 1.15
+13.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason Matuszewski | Chief Executive Officer, President, Secretary & Chairman | 1M | male |
| Andrew Vanvurst | Chief Operating Officer & Director | 1M | male |
| Michael Fortunato | Chief Accounting Officer | 506.3K | male |
| Brandon Poe | Chief Financial Officer | 45.0K | male |
| Irmgard Huber | International Medical Advisor & Interim Chief Medical Officer | — | — |
| Barry J. Hassett | Chief Commercial Officer | — | male |
| Jeff Humke | Vice President of Human Resources | — | male |
| Katherine Gorrell | Chief Legal & Compliance Officer | — | female |
| Larry Jones | Chief Revenue Officer | — | male |
| Noah Agron | Vice President of Corporate Finance & Strategy | — | male |
| David Woynarowski | Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BSEM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
